Merozoite surface protein 3 (MSP3)

Merozoite surface protein 3 (MSP3) is a 48-kDa secreted protein of the malaria parasite Plasmodium falciparum that becomes non-covalently associated with the merozoite surface [1]. While the N-terminal of the protein is highly polymorphic, the C-terminal region is remarkably conserved across various parasite isolates, making it a premier candidate for a universal malaria vaccine [2]. This conserved C-terminal region contains several B-cell and T-cell epitopes that are recognized by protective antibodies in individuals with naturally acquired immunity to malaria [3]. Unlike many other antigens, antibodies against the MSP3 C-terminal region do not primarily work by blocking erythrocyte invasion directly; instead, they act through Antibody-Dependent Cellular Inhibition (ADCI), a mechanism where antibodies bridge merozoites and monocytes to trigger the release of parasite-killing factors [4]. Clinical development has focused on various formulations, including the long synthetic peptide MSP3-LSP and the recombinant fusion protein GMZ2, both of which have demonstrated the ability to induce high titers of cytophilic antibodies and provide partial protection in clinical trials [5]. The target remains a focal point for blood-stage vaccine strategies due to its ability to elicit a robust, strain-transcending immune response [1][2].

Other names

MSP-3Secreted polymorphic antigen associated with merozoitesSPAMPF3D7_103540011.1 locus protein

Induction of protective IgG antibodies that facilitate Antibody-Dependent Cellular Inhibition (ADCI), where monocytes are recruited to inhibit the growth of Plasmodium falciparum blood-stage parasites.